



J. B. Chemicals & Pharmaceuticals Limited

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
 Corporate Office : Cnergy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400 025.
 Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334
 CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2017

Sl.No.	PART I - Particulars	Quarter ended			Year ended	
		6/30/2017	3/31/2017	6/30/2016	3/31/2017	
		Unaudited	Audited	Unaudited	Unaudited	Audited
1	Revenue from Operations	28,383.78	30,626.19	31,428.76	119,869.42	
2	Other Income	927.18	1,276.27	1,096.72	4,589.03	
3	Total Income (1+2)	29,310.96	31,902.46	32,525.48	124,458.45	
4	Expenses					
	a. Cost of materials consumed	8,818.82	9,131.39	9,555.32	36,709.36	
	b. Purchases of stock-in-trade	2,436.92	2,857.52	2,135.01	9,624.47	
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(134.24)	(663.24)	(174.06)	(1,805.26)	
	d. Employees benefits expense	5,582.17	4,989.62	4,620.50	18,786.11	
	e. Finance Costs	79.12	(24.05)	77.88	500.13	
	f. Depreciation and amortization expense	1,432.84	1,240.46	1,131.67	4,626.42	
	g. Other Expenses	8,573.34	9,623.41	8,370.83	34,338.86	
	Total Expenses (4)	26,788.97	27,155.11	25,717.15	102,780.09	
5	Profit before Tax (3-4)	2,521.99	4,747.35	6,808.33	21,678.36	
6	Tax expenses	485.26	532.44	1,822.83	4,381.90	
7	Net Profit/(Loss) after Tax and non controlling interest (5-6)	2,036.73	4,214.91	4,985.50	17,296.46	
8	Other Comprehensive Income (net of Tax)	(67.61)	(246.21)	(8.07)	(270.43)	
9	Total Comprehensive Income after Tax (7+8)	1,969.12	3,968.70	4,977.43	17,026.03	
10	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)					
	(1) Basic	2.32	4.68	5.88	20.07	
	(2) Diluted	2.32	4.68	5.88	20.07	

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on August 11, 2017.
- The sales in the domestic market were impacted as stockists scaled down their purchases in anticipation of introduction of GST due to probable financial impact associated with the pre-GST inventory. De-growth in profit was caused by lower sales and nature of the costs which are mainly fixed. The other factors that affected the profit were appreciation of Rupee against US \$ and higher manpower cost due to increase in domestic field force by over 600 people during last quarter of the previous year. However, this investment in manpower is expected to bring additional sales going forward.
- The Company has completed the buy-back of 12,50,000 equity shares of Rs. 2 each on July 25, 2017. Post buy-back, the share capital of the Company is Rs. 16,71,39,950 divided into 8,35,69,975 equity shares of Rs. 2 each.
- The auditors have carried out limited review of the financial results for the quarter ended on June 30, 2017 and their report does not contain any qualification.
- The Company has one reportable segment viz. Pharmaceuticals.
- The figures for the quarter ended on March 31, 2017 are the balancing figures between audited figures in respect of the year ended on March 31, 2017 and published year-to-date figures up to December 31, 2016.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

J.B.Mody
 Chairman & Managing Director

Place : Mumbai
 Date : 11/08/2017